Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
148
datasets available to search
ShareScore release 0.9.0
Dataset results
148 results for “Vemurafenib”
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
ClinicalTrials.gov study NCT02145143. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Vemurafenib and White Blood Cell Therapy for Advanced Melanoma
ClinicalTrials.gov study NCT01585415. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
ClinicalTrials.gov study NCT02303951. IPD Sharing: Not stated. Countries: 2. Publications: 1.
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
ClinicalTrials.gov study NCT03410875. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E Mutation
ClinicalTrials.gov study NCT03585686. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
ClinicalTrials.gov study NCT01683188. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metast
ClinicalTrials.gov study NCT02583516. IPD Sharing: NO. Countries: 1. Publications: 32.
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
ClinicalTrials.gov study NCT01656642. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
ClinicalTrials.gov study NCT02456701. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
ClinicalTrials.gov study NCT02089724. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery
ClinicalTrials.gov study NCT01787500. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
ClinicalTrials.gov study NCT01638676. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Figure 1 from: Neamah MJ, Al-Akkam EJM (2024) Preparation and characterization of vemurafenib microemulsion based hydrogel using surface active ionic liquid. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e111178
Figure 1 Pseudoternary phase diagram. A–C. Represent the pseudoternary phase diagram at the Smix ratios of 1:2, 1:3 and 1:4, respectively.
Figure 4 from: Neamah MJ, Al-Akkam EJM (2024) Preparation and characterization of vemurafenib microemulsion based hydrogel using surface active ionic liquid. Pharmacia 71: 1-9. https://doi.org/10.3897/pharmacia.71.e111178
Figure 4 Cumulative amount permeated per square centimetre versus time of different microemulsion-based hydrogel formulas.
A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
ClinicalTrials.gov study NCT01804140. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
ClinicalTrials.gov study NCT01765543. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
ClinicalTrials.gov study NCT01659151. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
ClinicalTrials.gov study NCT02050321. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
ClinicalTrials.gov study NCT01813214. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
ClinicalTrials.gov study NCT02230306. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.